InvestSMART

AFT Pharmaceuticals Limited (ASX: AFP) - Announcements

Current share price for AFP : $3.760 0.11 (3.01%)+

ASX company news and announcements for AFT Pharmaceuticals Limited (AFP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AFT Pharmaceuticals Limited (AFP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AFT Pharmaceuticals Limited (AFP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AFT Pharmaceuticals Limited (AFP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$394 Appendix 2A (Application for Quotation of Securities) 10 Jun 2020 8:26AM $4.570 $3.760 fallen by 17.72%
$394 Placement 10 Jun 2020 8:25AM $4.570 $3.760 fallen by 17.72%
$394 Placement 10 Jun 2020 8:25AM $4.570 $3.760 fallen by 17.72%
$394 Letter to Shareholders 5 Jun 2020 1:57PM $4.400 $3.760 fallen by 14.55%
$394 Annual Meeting and Closing Date for Director Nominations 5 Jun 2020 7:30AM $4.400 $3.760 fallen by 14.55%
$394 Secures Maxigesic IV distribution in 4 European countries 4 Jun 2020 7:30AM $4.600 $3.760 fallen by 18.26%
$394 Capital Change Notice - Issue of Ordinary Shares 26 May 2020 2:49PM $4.120 $3.760 fallen by 8.74%
$394 Appendix 2A 20 May 2020 7:35AM $4.080 $3.760 fallen by 7.84%
$394 Capital Change Notice 20 May 2020 7:35AM $4.080 $3.760 fallen by 7.84%
$394 Annual Report to shareholders 20 May 2020 7:34AM $4.080 $3.760 fallen by 7.84%
$394 Preliminary Final Report 20 May 2020 7:33AM $4.080 $3.760 fallen by 7.84%
$394 Preliminary Final Report - Investor Presentation 20 May 2020 7:32AM $4.080 $3.760 fallen by 7.84%
$394 Preliminary Final Report and Media Release 20 May 2020 7:32AM $4.080 $3.760 fallen by 7.84%
$394 AFP to announce full year results on Wednesday May 20 2020 5 May 2020 7:36AM $3.600 $3.760 risen by 4.44%
$394 Change of Director's Interest Notice 24 Apr 2020 7:50AM $3.850 $3.760 fallen by 2.34%
$394 Capital Change Notice - Issue of Ordinary Shares 24 Apr 2020 7:49AM $3.850 $3.760 fallen by 2.34%
$394 RLG: RooLife & AFT Pharmaceuticals - China Update 6 Apr 2020 9:57AM $4.000 $3.760 fallen by 6%
$394 Finalises refinancing and gives Trading Update 23 Mar 2020 7:32AM $3.500 $3.760 risen by 7.43%
$394 Market Trading Update 10 Mar 2020 12:15PM $3.100 $3.760 risen by 21.29%
$394 AFT on track to refinance CRG term loan facility 27 Feb 2020 7:32AM $3.100 $3.760 risen by 21.29%
$394 AFT licences Maxigesic IV in 21 new countries 5 Feb 2020 7:30AM $3.100 $3.760 risen by 21.29%
$394 Letter to Shareholders 23 Jan 2020 7:31AM $3.100 $3.760 risen by 21.29%
$394 Amended notice - Appendix 3B 17 Dec 2019 7:30AM $3.100 $3.760 risen by 21.29%
$394 Appendix 3B 16 Dec 2019 11:10AM $3.100 $3.760 risen by 21.29%
$394 AFT secures Maxigesic IV distribution in Indonesia 11 Dec 2019 9:40AM $3.100 $3.760 risen by 21.29%

276 - 300 of 546 results

Page 12 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.